Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 66 of 151

  1. IDE574

    IDEAYA Biosciences

    ER+, HER 2- Breast Cancer

    phase 2 small molecule active

    1 trial

  2. IDE849

    IDEAYA Biosciences

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

  4. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Unresectable/metastatic Small cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  5. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Chronic lymphocytic leukemia (CLL), Any type of B-cell lymphomas, Multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  6. IFCT-1904

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. IFCT-2003

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced ROS1-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  8. IFCT-2101

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  9. IFCT-2401 SPORADIC

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. IFCT-2502

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  11. IFG-05-2019

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  12. IFOM-CPT008/2022/PO0

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  13. IGEV

    Fudan University

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  14. IIBSP-HEA-2022-145

    The George Institute

    cognitive impairment

    phase 2 small molecule active

    1 trial

  15. IIT2014006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial

  16. IIT2024067

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 2 small molecule active

    1 trial

  17. IIT2024097

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 2 small molecule active

    1 trial

  18. IIT2025094

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CML,Blast Phase

    phase 2 small molecule active

    1 trial

  19. IIT2025111

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Waldenström Macroglobulinemia (WM)

    phase 2 small molecule active

    1 trial

  20. IJB-LBC-NEOCHECK2018

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

  21. IJB-REGINA-2020

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 small molecule active

    1 trial

  22. IJB-SYNERGY-012017

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 small molecule active

    1 trial

  23. IJB-ZEPHIR02-2024

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  24. IJB-ZEPHIR02-2024

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  25. IKF/AIO-ZANGEA

    The George Institute

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  26. IL-15-armored CAR-T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Multiple Myeloma

    phase 2 mab active

    1 trial

  27. IL-1Ra Kineret®

    United Therapeutics Europe Ltd

    Intracerebral Haemorrhage

    phase 2 small molecule completed

    1 trial

  28. IL-6 aGVHD Siltuximab: A phase II study to as...

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  29. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial

  30. IM045-1018

    Celgene Europe Limited

    Multiple Sclerosis Spasticity

    phase 2 small molecule active

    1 trial

  31. IMB101-010

    Lacuna Pharma Pty Ltd

    Non-obstructive hypertrophic cardiomyopathy

    phase 2 small molecule active

    1 trial

  32. IMC-M113V

    Immunocore Ireland Limited

    Chronic HIV infection

    phase 2 small molecule active

    1 trial

  33. IMC-R117C

    Immunocore Ireland Limited

    Cancer

    phase 2 small molecule active

    1 trial

  34. IMCIVREE 10 mg/ml solution for injection

    Disc Medicine

    ROHHAD syndrome

    phase 2 small molecule active

    1 trial

  35. IMCgp100-202

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 small molecule active

    1 trial

  36. IMD-1041

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  37. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    oligometastatic hormone sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  38. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)

    phase 2 small molecule active

    1 trial

  39. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy

    phase 2 small molecule active

    1 trial

  40. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  41. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with locally advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  42. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 small molecule active

    1 trial

  43. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  44. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously untreated

    phase 2 small molecule active

    1 trial

  45. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    unresectable stage III NSCLC (Non–small-cell lung cancer)

    phase 2 small molecule active

    1 trial

  46. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients With Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  47. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  48. IMFINZI for Metastatic pancreatic cancer

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.